---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016267"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:55:15.506065+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics Q1 2023 net loss $0.51/sh; cash $21.7M, runway into Q2 2024

## Summary
- R&D expenses $1.9M (+$0.6M YoY); G&A $2.6M (+$0.5M YoY); net loss per share $0.51 vs $0.41.
- Cash and equivalents $21.7M at March 31, 2023, down from $26.4M at Dec 31, 2022; cash runway into Q2 2024.
- First patient dosed in Phase 1 trial of Decoy20 for solid tumors in March 2023; three trial sites activated.
- Patent allowances in Brazil and India bring IP protection to 32 countries for Decoy platform.
- Robert Martell, M.D., Ph.D. elected to Board of Directors in February 2023.

## SEC filing metadata
- accession: 0001493152-23-016267
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/0001493152-23-016267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016267
- JSON: https://secwatch.observer/filing/0001493152-23-016267.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016267.txt

## Key facts
- Earnings Releases
  Indaptus Therapeutics, Inc. reported first quarter ended March 31, 2023 results: EPS approximately $0.51.
  - Period: first quarter ended March 31, 2023
  - EPS: approximately $0.51
  - Result: reported results
  source text: Loss per share for the three-month period ended March 31, 2023 was approximately $0.51 compared with approximately $0.41 for the three-month period ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/0001493152-23-016267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.